Archives

September 2010

• Drug Patent Challenge Report profiles companies that successfully challenged pharmaceutical drugs
• Orphan Drug Exclusivity profiles FDA-approved Orphan Drugs
• Cole-Parmer Introduces APEX 100 Metal Detectors from Thermo Scientific
• Deadline Nears for the Largest Drug Safety Summit held in the Western...
• Intrinsic Imaging Appoints Jatinder Kaur as Senior Director, Medical...
• Drug Patent Expirations in September 2010
• Drug Patent Expirations in September 2010
• Sacramento Law Firm Scrutinizes Johnson & Johnson Again, as the...
• Syngenta Strengthens U.S. Wheat Herbicide Portfolio with Development...
• New Guide Explores How to Recycle Carbon Emissions into Green Fuel
• Orbital Technologies Corporation (ORBITEC) Helps NASA Grow Vegetables...

August 2010

• Brinks Announces 2010 Innovation Competition Finalists
• Brinks Announces 2010 Innovation Competition Finalists
• Therapure Biopharma Inc.'s Drug Delivery Program for the Treatment of...
• Digital Pathology Services Firm Flagship Biosciences Creates...
• Orphan Drug Report
• Extech Video Borescope Inspection Cameras New from Cole-Parmer
• Extech Video Borescope Inspection Cameras New from Cole-Parmer
• Extech Video Borescope Inspection Cameras New from Cole-Parmer
• Extech Video Borescope Inspection Cameras New from Cole-Parmer
• Extech Video Borescope Inspection Cameras New from Cole-Parmer
• Johnson & Johnson's DePuy Orthopedics, Inc. Recalls the ASR XL...
• Invida to Participate in Key September Conferences in the U.S.
• Microsonic Systems Enters Asia-Pacific Market
• Putting China in Your Business Future ... Just Got Less Expensive
• Arrowhead Releases New Report Revealing Prospects for Traumatic Brain...
• Agile Sciences awarded NIH SBIR grant to validate biofilm dispersion...
• Medyssey Spine Receives FDA 510(k) Clearance for Zenius(TM)...
• The Workplace Group® Ranked #3 Mid-Market Provider of Recruitment...
• Quincy Bioscience Receives Investment Capital from DaneVest
• CAS Chemistry Research Report: A Decade Later Human Genome Discoveries...
• Novo Nordisk Creates “App” to Help Doctors Dose Insulin, Supporting...
• Bio Bank Helps Lethal Brain Cancer Patient Maintain Tissue Ownership Defy the Odds
• Healthcare Data Solutions Announces Segment Leader for Pharmacy...
• Coming soon - Biotechnology Entrepreneurship: From Science to Solutions
• Interact, Network and Exchange Opinions on Commercialization of...
• Cataract Surgery Goes 3D Hi-Def in Arkansas
• Mayo Clinic Doctors Plant the Seeds of Success in Cancer Surgery
• Synthetic Biology: Revolutionary or Evolutionary
• The Porcine microRNAome is Revealed
• Unigen Announces the Launch of Bakutrol™ - Powerful Triple-Acting Skin...
• Profile drugs with FDA regulatory exclusivity
• Senior FDA Speakers Discuss Emerging Issues In Cardiovascular Safety...
• Advanced Clinical Announces a Breakthrough Framework to Improve R&D...
• Haydon Kerk Motion Solutions, Inc. Announces New Online Prototype...
• The MedZilla Report for August 2010 - Health Care Job Creation Numbers...
• Broad Institute acquires license to all ChemAxon products and deploys across Chemical Biology Platform.
• Center For Medical Science Chemical Decontamination System
• Center For Medical Science Chemical Decontamination System
• How Genes Hide Their Function
• Undergraduates use Oxford Instruments MARAN Ultra Benchtop NMR...
• Quincy Bioscience Launches Animal Health Division
• UW Scientists Use 3D Cell Culture to Model Breast Cancer in...
• Business Video Site eCorpTV Welcomes Michael A. Colleran as Chairman...
• BiondVax Announces Receipt of Ethics (“Helsinki”) Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine
• Headwaters MB Adds to Life Sciences Team
• Zero Valent Iron for Soil and Water Remediation.
• Second Accelerator to More Than Double E-BEAM Services’ Medical...
• Ariadne, Cellecta and Roswell Park Cancer Institute to Collaborate on...
• Starting from Sand: Manufacturing Quality Labware on a Global Scale...
• Small-molecule Inhibitor Uncovers Protein Role in Melanoma Cell...
• Neumedicines Receives $2.5 Million from HHS/BARDA After Successful...
• Drug inventor report profiles individuals, US states, and countries leading pharmaceutical innovation
• Glidewell Laboratories Selects Objet Geometries to Offer Complete...
• DIA's Global Approach to Risk Management of Medicines Conference...
• iCardiac Reports Record Revenue Growth
• Pharmaceutical Development Services (PDS) and Schiff & Company Form...
• Healthcare Regulatory Professionals More Involved in Business and...
• RURO Launches Sciency ELN 2.0, a New Version of Electronic Lab...
• Improved Drop Setter Instrument for Protein Crystallization
• The University of Toronto Announces Free OpenHelix Tutorial and...
• MD Biosciences Preclinical Efficacy Models of Parkinson's Disease:...
• Experts Review of Chinese Cuvettes Reveals Astounding Results
• Recruiters Note Marked Improvement in the Job Market
• Global Spectrometers and Spectrophoto/Fluorometers Sales to Exceed...
• Duke Realty Unveils Enhanced Brand Identity
• Scientists Clarify Structural Sasis For Biosynthesis of Mysterious...
• International Hydroponics Expert Uses Pioneering New Hydroponics...
• Media Advisory: 21st International Symposium on Human Identification...
• RURO Announces Release of Sciency® 2.0 Standard Edition
• ion eXtra™ Trial Demonstrates that Electrolyte Balancing is the Way...
• Filter Testing - Understanding Filter Efficiency and Standards
• Green Wastewater Treatment Technology Secures $2 Million Investment
• Biomass Pellets Trade Asia, a Buyers and Sellers Meet, Explores...
• Solixia Receives National Cancer Institute SBIR Award
• New Binaural Technology from PranaHigh Eliminates the Need for...
• Who are the leading drug innovators, and where do they live?
• Drug Patent Expirations in August 2010

July 2010

• Synthetic Biology: What's the Agenda?
• Biotechnology and Business Publishing Opportunities: Blog posts, Journal Articles, Books, and Magazines
• Journal of Commercial Biotechnology -- July 2010 issue now available
• Building the Case for Biotechnology: Management Case Studies in Science, Laws, Regulations, Politics, and Business
• Biotech U -- Free online biotechnology course
• Drug Patent Expirations in July 2010

June 2010

• Biosimilar drugs to gain greater priority as decade progresses
• Biotechnology Management Papers, 2010
• Profitability and Orphans: The Role of Price and Incentives in Four Different Markets
• If You Build It, Will They Come?
• Patent Analysis: A Tool for Making Strategic Business Decisions
• Drug Patent Expirations in June 2010
• Coming soon: Building the case for biotechnology

May 2010

• Guest post: Healthcare Reform Bill Presents Significant Opportunity for Life Science Companies Engaged in Innovative Research
• Scientific American WorldView 2010: Measuring global biotechnology innovation
• Free access to the Journal of Commercial Biotechnology
• Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine
• 2010 Biotech Humanitarian Award goes to Robert Klein
• Scientific American Worldview rollout -- 3pm today
• Celebrating my (dissertation) independence day
• Booksigning at BIO 2010
• BIO2010 Day 2: Meetings
• Scientific American Worldview -- Measuring biotechnology innovation
• First day at BIO -- Getting Settled
• Drug Patent Expirations in May 2010
• Blogging from BIO2010

April 2010

• Journal of Commercial Biotechnology -- April 2010 issue now available
• Case studies in innovation: What enables outstanding achievements?
• Fulfilling Market Needs for Success in Biotechnology
• Next DCbiotech meeting: April 14th in Bethesda, with special guest
• Drug Patent Expirations in April 2010

March 2010

• Maryland Incubator Company of the Year Award Deadline Extended
• Coming soon - Get to Market Now!
• Do you work in biotechnology? Live in the DC area? Join DC Biotech!
• Educating the Next Generation of Biotechnology Managers and Founders
• Drug Patent Expirations in March 2010

February 2010

• My picks for the Biotech Humantarian Award
• Educating the Next Generation of Biotechnology Founders and Managers
• Drug Patent Expirations in February 2010

January 2010

• Seeking new editorial board members for the Journal of Commercial Biotechnology
• How do you train your new biotechnology employees?
• Scientific American worldView Interview available
• 2010 Biotech Humanitarian Award
• Journal of Commercial Biotechnology -- January 2010 issue now available
• Drug Patent Expirations in January 2010

December 2009

• Top 4 Healthcare Predictions for 2010
• India, Intellectual Property and Biotechnology Industry

November 2009

• Drug Patent Expirations in December 2009
• Perspectives on the Kyoto Prize
• Is the practice of medicine impeding medical innovation?
• Drug Patent Expirations in November 2009

October 2009

• Biologic data exclusivity: The arguments for and against it
• Kyoto Prize Journalism Fellowship
• Drug Patent Expirations in October 2009

September 2009

• Journal of Commercial Biotechnology -- October 2009 issue now available
• Pfizer's Power on Individualized Medicine
• Introducing DCbiotech -- High-level networking in the nation's capital
• Drug Patent Expirations in September 2009

August 2009

• Biotechnology green shoots?
• Jim Greenwood on Data Exclusivity and Healthcare Innovation
• The impact of the global financial crisis on biotechnology development
• Drug Patent Expirations in August 2009

July 2009

• Naturally Obsessed: The Making of a Scientist
• Drug Patent Expirations in July 2009

June 2009

• Journal of Commercial Biotechnology -- July 2009 issue now available
• Innovating Across Borders
• Koronis: Developing a new treatment for HIV
• Drug Patent Expirations in June 2009

May 2009

• Biotechnology Management Papers
• The changing roles of CRO
• Discovering potential drug targets
• Financial opportunities for early stage biotech companies
• Discussing the worldVIEW Project
• Biotech protesters and the economic crisis
• Scientific American WorldVIEW: Measuring Global Biotechnology Innovation
• VC's don't read business plans; So, what to do?
• Measuring Global Biotechnology
• Creative Destruction in Biotechnology
• Drug Patent Expirations in May 2009

April 2009

• Assessing India's Innovation Climate
• An Overview of the Biopharmaceutical Landscape Ahead
• Measuring global biotechnology innovation
• Drug Patent Expirations in April 2009

March 2009

• Will Roche Spin Genentech Off Again?
• Entrepreneurship: What Not to Do
• Journal of Commercial Biotechnology -- April 2009 Special Issue on Education
• Drug Patent Expirations in March 2009

February 2009

• Call for chapters - Biotechnology Marketing
• Drug Development – Balancing National and Commercial Needs
• Biotechnology Certificate Program at JHU's Carey School of Business
• Drug Patent Expirations in February 2009
• Solving the FDA Crisis

January 2009

• The Critical Reasons You Need to Plan Your Business, then Work Your Plan
• Introducing BiotechBistro.com
• 2008 in Review
• Introducing Biotech-U: Web-based courses on biotechnology
• Drug Patent Expirations in January 2009

December 2008

• Journal of Commercial Biotechnology -- January 2009
• Instructor resources for Building Biotechnology
• Biotechnology and the Global Financial Crisis
• Ranking International Biotechnology
• Drug Patent Expirations in December 2008
• Spread your message with BiotechBlog

November 2008

• Join the Journal of Commercial Biotechnology Discussion Group
• Slow Posting -- New Project in the Works
• Drug Patent Expirations in November 2008

October 2008

• Journal of Commercial Biotechnology -- October 2008
• Intellectual Property Theft on the Rise
• Biotechnology Career Development
• Seeking experienced industry insiders for book series
• Drug Patent Expirations in October 2008

September 2008

• When will the U.S. develop concise generic biologic rules?
• Commercializing biotechnology in China
• Drug Patent Expirations in September 2008

August 2008

• Contract research helps keep drug pipeline flowing
• Building Biotechnology 3rd Edition now available
• Beyond the Business Plan: Managing unexpected risk in biotechnology business development
• Drug Patent Expirations in August 2008

July 2008

• Roche and Genentech's mating dance -- This isn't the first time
• Background: The Clinical and Translational Science Awards Consortium (CTSA program)
• Why the market does not like Flurizan
• Advertise on Biotechblog
• Journal of Commercial Biotechnology -- July 2008
• Looking for writers for book projects
• Drug Patent Expirations in July 2008

June 2008

• Dyadic founder regains control
• Six Pitfalls to Avoid in Supplier Management
• Reminder: BIO2008 Session
• Reminder: BIO2008 book signing
• Drug Patent Expirations in June 2008
• Seeing the Field

May 2008

• Promote your expertise
• Call for papers: Biotechnology Investing
• BIO2008 book signing
• Seeking reviewers and contributors for next edition of Building Biotechnology
• Dyadic founder fights to regain control of company
• Drug Patent Expirations in May 2008

April 2008

• Why so quiet?
• Journal of Commercial Biotechnology -- March 2008
• Drug Patent Expirations in April 2008

March 2008

• Upcoming talks
• New Biotechnology Books on Biotechnology Business Development and Biotechnology Education
• Drug Patent Expirations in March 2008

February 2008

• Generic Biologics: How to Compete
• BIO's website hacked?
• Upcoming talk: Forget everything you thought you knew about biotechnology entrepreneurship
• An appeal for generic biologic legislation
• Drug Patent Expirations in February 2008

January 2008

• New Biotechnology Books
• Want biotechnology venture capital? Use a shotgun!
• Journal of Commercial Biotechnology - Free Issue!
• Drug Patent Expirations in January 2008

December 2007

• Biotechnology in Turkey
• FDA Enforcement Trends: 2007-2008
• Drug Patent Expirations in December 2007

November 2007

• Venture Capital Returns
• Call for Papers: Biotechnology Marketing
• Career Development in Biotechnology
• Rethink PCR
• Drug Patent Expirations in November 2007

October 2007

• Happy 25th, Humulin
• Exubera: The road to hell is paved with good intentions
• Biotech for Turkey
• Journal of Commercial Biotechnology
• Pharma to support the international space station?
• Drug Patent Expirations in October 2007

September 2007

• Manufacturing is dead. Long live manufacturing!
• Upcoming events
• Building Biotechnology on Facebook
• Drug Patent Expirations in September 2007

August 2007

• Amgen's patents protect Epogen. Again.
• Drug approvals fall. Who's to blame?
• Carnival of Biotechnology
• Journal of Commercial Biotechnology
• Call for chapters: Best practices in biotechnology business development
• Drug Patent Expirations in August 2007
• Carnival of Biotechnology

July 2007

• Expanding the bandwidth of life science investments: Increasing investment viability
• Call for Papers: Journal of Commercial Biotechnology
• Offshoring and U.S. Biotech Labor Shortages
• `Til Death Do Us Part, But First, the Pre-Nup: Why CAPA Needs to Evolve
• Drug reimportation: Where are the dead Canadians?
• Starting a biotechnology company to treat a child
• More details on Google Health
• Drug Patent Expirations in July 2007

June 2007

• Carnival of Biotechnology
• Inhalable Insulin: The Future Is Now
• Off to Toronto
• Google's healthcare ambitions -- the ultimate second opinion
• Shuffling off to Buffalo
• Patenting synthetic life
• Indian pharma scientists commanding U.S. wages - in India
• Herbert Boyer
• Functional Overview of the Biotechnology Industry
• Drug Patent Expirations in June 2007

May 2007

• Carnival of Biotechnology
• The global spread of biotechnology
• A new journal in town...
• Career Development at UNC Chapel Hill
• Greenpeace a champion for genetic modification?
• Top five biotechnology blogs
• Indian biotechnology: Full of promise, challenged by patents
• Drug Patent Expirations in May 2007

April 2007

• Tell me about your career
• Update on the price control power struggle
• Biotech 360
• Abbott Gets Tough with Thailand
• Carnival of Biotechnology
• Upcoming Events
• Write a chapter for my book on Advanced Topics in Biotechnology Business Development
• Drug Patent Expirations in April 2007
• Genentech goes offshore

March 2007

• Patent licensees gain more power
• Carnival of Biotechnology
• Xenotourism: Scary Stuff
• The commercial prospects of biogenerics - how much will they save?
• VCs filling biotech funding gap
• Angels filling biotechnology funding gap
• Looking beyond traditional markets
• Price controls and compulsory licensing give buyers more power ... for a price.
• Carnival of Biotechnology
• Why are biogenerics so hard to regulate?
• Drug Patent Expirations in March 2007

February 2007

• Open Biotechnology Journal
• Carnival of Biotechnology
• Drug Patent Expirations in February 2007

January 2007

• Carnival of Biotechnology
• Lessons and analogies from other industries
• Can Science Be a Business?

December 2006

• Carnival of Biotechnology

November 2006

• Carnival of Biotechnology

October 2006

• Carnival of Biotechnology

July 2006

• Carnival of Biotechnology

May 2006

• Carnival of Biotechnology

April 2006

• Carnival of Biotechnology
• Carnival of Biotechnology

March 2006

• Carnival of Biotechnology

February 2006

• The Inaugural Carnival of Biotechnology
• Announcing the Carnival of Biotechnology
• New Host

January 2006

• Free market for biotech patents?
• Will Human Genome Sciences finally be able to manufacture something in its new plant?

December 2005

• ‘Canadian’ pharmacies not actually in Canada…
• Scripps Institute proposes new Florida site for biotech park
• Intellectual Property: Last chance for Europe’s biotech pioneers

November 2005

• Financial Snapshot For September 2005

October 2005

• Overcoming Offshoring in Biotechnology

August 2005

• Bear Stalking Biotech Sector

July 2005

• Financial Snapshot For June 2005
• India needs a body like FDA for quality control in drugs

June 2005

• U.S. relatively hospitable to stem-cell research

May 2005

• Drug firms don't disclose enough
• Alternative Stem Cell Bill Added to Debate
• Giving The Green Light To Industrial Biotech
• Genentech's Lessons For Big Pharma

April 2005

• Brand Drug Prices Outpace Inflation
• Clones' beef, milk same as regular

March 2005

• FDA guidelines to help personalized drug development
• India Proposes End to Patent Drug Copying
• Nearly 50 new biotech medicines in pipeline

February 2005

• Biotech Buyout Binge Continues
• Ad Changes Ahead for Controversial Drugs
• Drug Patent Approvals
• U.N. Calls for Clone Ban
• Will California's Stem Cell Initiative Reap Royalties?
• FDA Plans New Board To Monitor Drug Safety
• More Roadblocks Ahead For Pharma in 2005?
• Genetically Modified IP Launched
• From the laboratory to the investment fund
• Biotech: A Big Future Behind It?
• The State of Stem Cell Research
• The Human Genome, Take Two

January 2005

• Big Pharma's Ails Could Spread To Biotech
• Financial Snapshot For December
• Biotech Foods Without the Fear Factor
• Big Changes for Big Pharma
• Biotechs forced to work harder to fill openings
• Merck Outlines Vioxx Defense

December 2004

• Survey Shows Lack of Confidence at FDA

November 2004

• Bill Aims to Protect Joint Patents
• Trouble for California Cloning?
• The Murky History of Merck's Vioxx
• Contingency Plans Help Current Merck Crisis
• Reviewing Drug Safety
• The Stem Cell Gold Rush

October 2004

• Financial Snapshot For September 2004
• Biotech: The "safe" drug bet?
• Biotech execs have a sense of humor about elusive profits
• Is That a Pilot in Your Pocket?
• Foresight or folly? Generics firms' foray into NCEs
• How many trillions for a drug miracle?
• State biotech sector no miracle drug for creation of jobs
• Merck: Successor pill safer than Vioxx
• Big pharma's pain could be biotech's gain
• Few Americans Buy Meds Online
• The Waning Of The Blockbuster Drug
• Financial Snapshot For September 2004
• Beleaguered Merck looks to future

September 2004

• FDA Eases Rules on Drug Manufacturing
• Online Extra: "It's a Perfect Storm" for Drugmakers
• "It's a Perfect Storm" for Drugmakers
• Long Trip for Psychedelic Drugs
• Genetically altered grass spreads like wildfire
• How Dublin Keeps Big Pharma Happy
• The Trials of ImClone
• Drug Patent Expirations in September 2004
• The Time Is Right for These Seven Biotechs

August 2004

• Biotech Knockoffs Lure Novartis
• Biotech returning to favor
• Drug firms in United States, Europe move biotech work to India

July 2004

• Singapore Wants You!
• Biotech's Longer Convalescence
• China: how to seize "commanding point" of biotechnology
• Stem-Cell Cash on a Winding Road
• Financial Snapshot For June 2004
• ImClone Hammered as Sales Lag Estimates

June 2004

• Wanted: Drugs to Fight Bioterror
• Eco-Terror Cited as Top Threat

May 2004

• The Drug Research War
• Biotechs struggle as IPOs find cool reception
• The Health-Care Catastrophe That Won't Happen
• Will U.S. try to circumvent drug firms patent?
• Another gene genie out of the bottle
• Could patients glean stock tips?: Drug trial participants may be insider trading.
• Financial Snapshot For March 2004: Looking Good

April 2004

• Full Steam Ahead
• Money-Back Guarantee On Rx Drugs
• Can the world afford to reject GM foods?
• Are biotech jobs next to go?
• Financial Snapshot For March 2004
• Drug Company Accused of Bribing Doctors
• Has Obesity Met Its Match?
• "Pssst ... Wanna Buy Some Augmentin?"

March 2004

• The 5% Shuffle - How not to get funded
• A Drug Behemoth In The Making?
• Is genetic engineering next doping threat?
• Boy May Force Change in Norway Bio-Ethics Law
• Drug Prices: The Genentech Solution
• Amgen Opens The Secret Curtain
• Biotech uptick moves into March
• And When ImClone's Drug Doesn't Work...

February 2004

• The perilous path of biotech drugs
• Feds to Biotech: No More Fibbing!
• Pfizer Wins One For Sane Patents
• Hospital ventures into stem-cell reimplantation
• Cloning Creates Human Embryos
• Doctors Call for Abbott Boycott on AIDS Price Hike
• FDA a Big Winner In '05 Bush Budget
• Plants to uncover landmines
• Drug may give cells a fresh start
• On thin ice: how the quest for a billion-dollar microbe is running out of control in Earth's last wilderness
• Management issues challenge biotech startups
• Monsanto: Ready to Blossom?

January 2004

• FDA big factor behind high US drug costs
• FDA Begins Push to End Drug Imports
• What To Expect From A Venture Capitalist
• Is ImClone Out of the Woods?
• What's in a Drug Name?
• Rise in biotech lawsuits
• Agriculture Department looks at revamping biotech rules
• Making Way for Designer Insects
• Biotech firms urge Canada to uphold canola patent
• Biotech Limits Found Lacking
• FDA's economist in chief
• Biotech IPOs; don't let the numbers deceive
• Purple Haze
• Financial Snapshot For December 2003
• What's Next for Pharma?
• India: Big Pharma's New Promised Land?
• Genetically engineered Glofish spark controversy
• Feeling Lucky?
• Biotech industry raises $16.4B in new funding in 2003
• Baby Steps

December 2003

• A Happy Pill for Some Biotechs
• Biotech: A Coming Boom -- or Bust?
• Biotech may be poised for "big year"
• Got Life?
• When Patents Persist
• Amgen's Cannibalistic Ways
• FDA Chief Eyes Path for Copycat Biotech Drugs
• Boston's Biotech Moment
• Professor, Biotech Butt Heads
• Tech Transfer: The Ties That Bind
• Drug companies make patent concessions
• Dutch Official Calls on Europe to Open Markets to Biotech Foods
• Financial Snapshot For November 2003
• A dietary magic bullet?
• FDA, Industry Collaborate On Genomics Guide
• Canola Case Tests GMO Patent
• Food Biotech Is Risky Business

November 2003

• NBI On Drugs
• Glowing red GM fish to sell in US
• Slowdown casts doubt on biotech offerings
• Machine Could Sequence Human Genome in a Year
• Biotech Raises More Cash in 2003 But Europe Weak
• Is That Daylight for ImClone?
• Over the Rainbow Yet?
• Ultimate Analysis
• COUNTERING COUNTERFEITS
• BAYER CHEMICALS TO TAKE A SPIN
• BIOTECH SCORES BIG THIRD-QUARTER GAINS
• DRUG EARNINGS RALLY IN THE THIRD QUARTER
• It Lives for 29 Years?
• Big pharma plays hard ball with little biotech
• USDA Sued Over Drug-Growing Crops
• Staffing needs seen in biotech industry
• Getting Investors' Pulses Beating Again
• Financial Snapshot For October 2003
• Vatican steps in on biotech foods debate
• A survey of strategic licensing practices in the pharmaceutical industry
• The Generic Retribution
• October sees a frenzy of biotech IPOs
• Venture Financing: Ready To Rebound?
• Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries
• Gene Tests? Not So Fast
• States flock to biotech like gamblers to lottery tickets

October 2003

• In Initial Finding, FDA Calls Cloned Animals Safe as Food
• Biotech Startups: Take Your Time
• Has the debate on GM crops been misleading?
• Are Adult Stem Cells a Bust?
• Is the US pharmaceuticals industry losing its way?
• U.S. drug companies curb supplies to Canadian exporters
• The next big thing is...
• Pharmaceutical Makers Turn To CRM
• Fog Begins to Lift with Q3 Biotech Numbers
• India emerges as new drug trial hot spot
• Who's Going To Pay For Global Health?
• Seeking a Prescription for Biogenerics
• Why Merck Missed the Mark
• Biotech: Teva's Next Triumph?
• Gene Therapy Rebuilds Gums
• Is Viagra Vulnerable?
• It's Wake-Up Time
• Biotech plans: Boon or fantasy?
• REDISCOVERING NATURAL PRODUCTS
• Biotech funding on track to bounce back
• Popping a pill could fix gene defect
• Monsanto Overhauling Businesses
• Cloning Remains a Meaty Issue
• Sabotage of biotech firms grows
• High hopes for biotech companies / IPOs getting ready to go as startups woo VC investors
• Reducing Multi-Cycle Reviews Is FDA Priority
• Reaping and Sewing From Corn
• Enigmatic ImClone
• IPO market abuzz with biotech offerings
• IPO Market Abuzz with Biotech Offerings
• GE's Genomic Future
• Financial Snapshot For September 2003
• Medicine's Big Bottleneck
• Stem cell bill eyed as lure to biotech firms
• What's Really Banging Up Biovail?
• European biotech - surviving the storm
• Pharma marketing's changing skills set
• Create Competition In Expanding Biotech Field
• Bacteria Make More Electricity
• Geneticists hunt control patterns
• Faster Entry Sought for Generics
• Biotech IPO Pipeline Fills Up
• Financing On Target For A Stellar Year
• GM crops in Brazi
• Affymetrix sells new gene chip / Chip represents full human genome
• Wound drug 'could speed healing'
• Genentech Will Ride Out Drug Failure

September 2003

• Genentech's CEO on Big Pharma's Issues
• FDA's McClellan Calls for More Sharing of Drug R&D Costs
• Drug Development, Genentech Style
• BIOTECH THAWS OUT
• Suit targets 13 generic drug makers
• Judge Allows Antitrust Case Against Seed Producers
• Definitions Impede Stem-Cell Work
• Bioterror Brain Drain
• A dose of reality
• Naturally blonde, brunette...
• Venter Announces $500K Prize for Significant Advances Toward $1,000 Genome
• The Odd Couple - CombinatoRx brings matchmaking to drug discovery and development
• GlaxoSmithKline Reveals Ingenuity
• The Best in Drugs and Biotech
• What VCs Don't Tell You
• Building a Better R&D Mousetrap
• A WTO deal on drugs

August 2003

• Biotechs big winners in VC rebound
• Vatican in favour of GM Food
• Genetically engineered trees sprouting quietly... for now

July 2003

• Antibiotics, The Next Generation
• The War against 'Viagra'
• BIO leader hits proposal for drug price regulation
• Biotech industry in survival mode
• The genetically-modified food fight
• No simple generic answer
• Antibacterials: a dying trade
• Financial Snapshot For June 2003: Taking A Breather
• Pfizer's Quest to Stay Ahead of the Pack
• Can Your Genomics Work Contribute to Biodefense

June 2003

• Biogen/Idec: still a matter of size
• The State of Biotechnology
• Coffee Plants Can Produce Less Caffeine
• Pfizer's Outlook Improves
• Schering's Dr. Feelbetter?
• FDA approves first nasal mist flu vaccine
• Microsoft loses No. 2 ranking in market value to drug maker
• Report Says More Farmers Don't Follow Biotech Rules
• More regulations for biotech products aren't necessary, FDA says
• Pfizer unveils anti-smoking drug
• New Drug Rules Aim To Speed Generics
• RNAi Firms Stake Their Claims
• More U.S. Investment in Biotech Needed, USAID Chief Says
• Wake Up and Smell the Science
• Biotech Investors: When Will They Ever Learn?
• Drug ads deliver a few side effects
• Biotech Industry Could Turn Profitable This Decade
• Biotech firms eye rally hungrily
• Biotech Stock Report - WOW!
• Schering-Plough: Drugmaker, Heal Thyself
• Geron's the Biotech of the Day
• India 'to approve GM potato'
• Genentech's Next Move
• This Dutchman Is Flying
• GM crops 'good for developing countries'
• BIOTECH RALLIES
• Financial Snapshot For May 2003: Yee Hah
• BIOTECH TEMPERATURE RISES
• Biotech is benign
• Science and Law: Swapping the lab for the law
• Biotech sector keeps surging / Cancer drug news and FDA approvals create optimism
• Early stage biotechnology collaborations
• FDA chief looks to speed diabetes, obesity drugs
• Pfizer sues over counterfeit Lipitor
• The ImClone Story: A Hyped Drug, a Tainted Icon
• Five Hurdles for Biotech
• San DNAgo
• Puncturing The ImClone Hype

September 2002

• China's Killer Headache: Fake Pharmaceuticals

August 2002

• Looking beyond Patent Expiry
• Modified pigs are transplant 'breakthrough'
• Send in the Clones
• New breed of VCs banking on biotech
• Biology Seeks a Few Good Geeks
• Biotechs on edge as money evaporates
• Making a Run for the Border-For Canadian Prescription Drugs
• Biotech industry seeks control of its destiny
• Singapore's biotech bid

July 2002

• Big Pharma: Getting Too Big for Its Own Good?
• European Patent Office bars human cloning in patent
• Woman carries human clone, group says
• Monoclonal Antibodies Look to a Bright Future
• Genomics Sector Has Fired More Than 1,500 Staff Since January 2001
• Biotech Not Cratering, Just Deflating
• Cuba seeks new drug markets
• Time to Let the Air Out
• FDA rules need tweaking

June 2002

• deCODED?
• Will R&D Make Merck Hot Again?
• Cracking the cancer code
• Report raps drug firms' 'post-approval' studies
• Of Clones and Clowns
• Legal Circumvention
• 5 Big Drug Companies Face R&D Drought
• Informatics Moves to the Head of the Class
• Nanopharmaceuticals Open Up Brand New Field Of Study
• Networked Pharma
• Pharma Financial Squeeze Bodes Ill for Genomics
• DeCode's Genetic Breakthrough Barely Registers
• Celera abandons gene sequencing
• Biotrends
• Where the Biotech Bets Are
• Biotech lobbyists' clout grows in Washington
• Gene Doping Threatens to Transform Sports

May 2002

• FDA Acts To Speed Bioterror Medicines
• A Challenge to Science and Nature
• Life after Venter
• Biotech heads west for VC
• Cloning Bill Bans Abortion Too?
• Biotech Banker Predicts More Meetings But Fewer Attendees
• Faulty Genes Explain Why Cloning Is So Difficult
• Two New Bills Present Challenges to DNA Patentability
• Biotech industry's still waiting to break out
• Rating the Nation's Best and Worst Jobs
• Battling Hunger With Biotechnology
• Motorola shedding biochip biz

April 2002

• Drug makers need a cure for the manufacturing crunch
• Celera Shifts Marketing of Database
• Was the U.S. government cheated on DNA decoder?
• Cultivating Prosperous Partnerships
• Harvesting the Fruits of Plant Genomics
• Pa. uses tobacco settlement to fund biotech
• Biotech stocks show indication of rebounding
• Chinese cloning control required
• Veteran biotech investors offer tips from trenches
• Genome Group Rips Human Cloning
• As Pipelines Wither, Pharma and FDA Explore Whether Microarrays are Ready for Primetime
• Research 'leak' hits Genentech
• As Tony White Reads Resumes, Industry Buzzes Around Core Four
• President Presses Senate to Ban All Human Cloning
• 7 drug makers unveil elderly discounts
• Survival of fittest is new mode for biotechs
• Biotech booster shot
• Bad Genes, Good Drugs
• New `greenhouses' to promote biotechnology businesses
• Biotech industry in race for space